BRPI0812465A2 - Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1 - Google Patents

Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1

Info

Publication number
BRPI0812465A2
BRPI0812465A2 BRPI0812465-5A2A BRPI0812465A BRPI0812465A2 BR PI0812465 A2 BRPI0812465 A2 BR PI0812465A2 BR PI0812465 A BRPI0812465 A BR PI0812465A BR PI0812465 A2 BRPI0812465 A2 BR PI0812465A2
Authority
BR
Brazil
Prior art keywords
antibody fragment
soluble antibody
fragment expression
domain truncation
truncation
Prior art date
Application number
BRPI0812465-5A2A
Other languages
English (en)
Inventor
Jon C Mitchell
Diane Retallack
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Publication of BRPI0812465A2 publication Critical patent/BRPI0812465A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0812465-5A2A 2007-06-08 2008-06-06 Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1 BRPI0812465A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94299707P 2007-06-08 2007-06-08
PCT/US2008/066187 WO2008151319A2 (en) 2007-06-08 2008-06-06 Expression of soluble antibody fragment by truncation of ch1 domain

Publications (1)

Publication Number Publication Date
BRPI0812465A2 true BRPI0812465A2 (pt) 2014-12-02

Family

ID=40076617

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812465-5A2A BRPI0812465A2 (pt) 2007-06-08 2008-06-06 Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1

Country Status (9)

Country Link
US (1) US20090042254A1 (pt)
EP (1) EP2160405A2 (pt)
JP (1) JP2010528664A (pt)
KR (1) KR20100021627A (pt)
AU (1) AU2008261042A1 (pt)
BR (1) BRPI0812465A2 (pt)
CA (1) CA2689556A1 (pt)
MX (1) MX2009013393A (pt)
WO (1) WO2008151319A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
HUE043556T2 (hu) * 2009-12-10 2019-09-30 Regeneron Pharma Nehézlánc antitesteket elõállító egerek
DK3039038T3 (da) * 2013-08-30 2021-02-08 Aprilbio Co Ltd Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
MX2019013750A (es) * 2017-05-19 2020-07-20 Council Scient Ind Res Un metodo para producir ranibizumab humanizado recombinante replegado.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005003169A2 (en) * 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody

Also Published As

Publication number Publication date
EP2160405A2 (en) 2010-03-10
WO2008151319A2 (en) 2008-12-11
WO2008151319A3 (en) 2009-03-26
AU2008261042A1 (en) 2008-12-11
MX2009013393A (es) 2010-02-09
JP2010528664A (ja) 2010-08-26
CA2689556A1 (en) 2008-12-11
AU2008261042A2 (en) 2010-01-28
KR20100021627A (ko) 2010-02-25
US20090042254A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0816846A2 (pt) Mecanismo de ativação
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0818349A2 (pt) Dispositivo de reconstrução
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0912242A2 (pt) mecanismo de trava
BRPI0821162A2 (pt) Dispositivo de maçaneta
FI20070231A0 (fi) Laite nanoputkien tuottamiseksi
EP1987064A4 (en) DOMAIN ANTIBODY CONSTRUCT
CR10705A (es) Anticuerpos para linfotoxina-alfa
DE112009000964A5 (de) Tampon
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0813819A2 (pt) mecanismo de trava
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
BRPI0819765A2 (pt) Conjugados de anticorpos anti-rg-1
BRPI0807858A2 (pt) Anticorpo de modificação de doença cancerosa
BRPI0912769A2 (pt) anticorpos anti-pirb
BRPI0812465A2 (pt) Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1
BRPI0810427A2 (pt) Filatório de extremidade aberta
BRPI0915517A2 (pt) sacarídeos vi conjugados

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]